KIMS: Tier-2 Growth, Shareholder Test

KIMS is expanding fast, and that is the core investment story. The company reported FY25 revenue of about ₹3,067 crore, and recent quarterly revenue crossed ₹1,000 crore, but profits have been under pressure as new hospitals ramp up. The company’s operating base is also growing quickly. One recent report said KIMS had 5,994 beds across 20 hospitals in Q4 FY25, and another noted a plan to reach more than 8,000 beds by FY27E. That kind of scale-up can create long-term value if occupancy rises and new beds start generating healthy returns. From a shareholder view, the opportunity is real. Tier-II and regional markets are seeing stronger demand for quality healthcare, and KIMS is trying to capture that demand early by adding capacity in high-potential clusters. If the beds fill up well, revenue growth can stay strong and margins can improve as fixed costs get spread across a larger base. The risk is equally important. In Q3 FY26, KIMS reported revenue of ₹1,003 crore, EBITDA of ₹204 crore, EBITDA margin of 20.4%, and PAT of ₹52 crore, showing that rapid expansion can temporarily hurt profitability. A separate update also said cash and cash equivalents were ₹120 crore as of September 2025, while the board approved a plan to raise up to ₹1,500 crore through QIP, which could support growth but may dilute existing shareholders. So, KIMS can be a good long-term shareholder story only if execution stays strong. The stock can benefit from higher bed capacity, better regional reach, and rising healthcare demand, but investors should watch utilisation, margins, and dilution closely.